Polymerizing fibrin decreases the polyphosphoinositides in chymotrypsin-treated human platelets.
Vickers
J D
JD
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
Packham
M A
MA
Kinlough-Rathbone
R L
RL
D012103:Batroxobin / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002918:Chymotrypsin / Q000494:pharmacology*; D005337:Fibrin / Q000187:drug effects / Q000378:metabolism / Q000494:pharmacology*; D005340:Fibrinogen / Q000494:pharmacology; D006801:Humans; D007294:Inositol / Q000097:blood; D007295:Inositol Phosphates / Q000097:blood; D009842:Oligopeptides / Q000494:pharmacology; D010710:Phosphates / Q000097:blood; D018129:Phosphatidylinositol Phosphates / Q000097:blood*; D010761:Phosphorus Radioisotopes; D010974:Platelet Aggregation; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011865:Radioisotope Dilution Technique; D014316:Tritium
D007295:Inositol Phosphates; D009842:Oligopeptides; D010710:Phosphates; D018129:Phosphatidylinositol Phosphates; D010761:Phosphorus Radioisotopes; D010975:Platelet Aggregation Inhibitors; D014316:Tritium; D007294:Inositol; D005337:Fibrin; D005340:Fibrinogen; C046617:arginyl-glycyl-aspartyl-serine; D012103:Batroxobin; D002918:Chymotrypsin